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Trefoil factor 1 (TFF1, also known as pS2) is strongly expressed in the gastrointestinal mucosa and plays a
critical role in the differentiation of gastric glands. Since approximately 50% of all human gastric cancers
are associated with decreased TFF1 expression, it is considered a tumor suppressor gene. Tff1 deficiency
in mice results in histological changes in the antral and pyloric gastric mucosa, with severe hyperplasia
and dysplasia of epithelial cells, resulting in the development of antropyloric adenoma. Here, we generated
Tff1-knockout (KO) mice, without a neomycin resistant (NeoR) cassette, using the clustered regularly
interspaced short palindromic repeats/CRISPR-associated nuclease 9 (CRSIPR/Cas9) system. Though our
Tff1-KO mice showed phenotypes very similar to the previous embryonic stem (ES)-cell-based KO mice,
they differed from the previous reports in that a reduction in body weight was observed in males. These
results demonstrate that these newly established Tff1-KO mice are useful tools for investigating genetic
and environmental factors influencing gastric cancer, without the effects of artificial gene insertion.
Furthermore, these findings suggest a novel hypothesis that Tff1 expression influences gender differences.
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Gastric cancer is one of the most common types of
cancer and is the second leading cause of cancer deaths
worldwide [1-3]. It accounts for approximately 10% of
newly diagnosed cancers [1], however, its diagnosis
usually occurs at an advanced stage, which is one of the
main reasons for its high mortality rate [4]. Therefore,
the detection and diagnosis of gastric cancer at an early
stage are important for its successful treatment. Studying
models of early gastric cancer will help achieve this goal.
A significant decrease in Trefoil factor 1 (TFF1)
expression occurs in approximately 50% of all human
gastric cancers [5,6]. TFF1 encodes a small precursor
protein of 84 amino acids, containing peptide sequence
characteristics of secreted proteins [7,8]. The mature
form of TFF1 is secreted by mucus-secreting pit cells in
the corpus and pyloric antral region of the stomach, as
a 60-amino-acid peptide consisting of a trefoil domain
and a C-terminal dimerization domain [7]. It is implicated
in many gastrointestinal cell biological processes, including
repair, protection, cell proliferation, differentiation, and
migration [9,10]. Depletion of Tff1 in mice results in the
development of antropyloric adenoma, with severe
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hyperplasia and dysplasia of epithelial cells in the
antropyloric region [4,8]. This indicates that Tff1 functions
as a gastric tumor suppressor gene. Therefore, a Tff1-
knockout (KO) mouse would a useful model to dissect
the early events of gastric carcinogenesis and to
investigate aspects of gastric cancer that are difficult to
study in humans.
Clustered regularly interspaced short palindromic
repeats (CRISPR)/CRISPR-associated nuclease 9 system
(Cas9) technology is a useful tool to generate KO mouse
models by simple genome editing. The Cas9 nuclease
protein, derived from Streptococcus pyogenes, recognizes
the protospacer adjacent motif (PAM) sequence, 5-
NGG-3, in the target DNA. The sgRNA, consisting of a
fusion of tracrRNA and crRNA, containing a sequence
complementary to the 20 nucleotides upstream of the
PAM, is required for recognizing the target site [11].
Cas9/sgRNA complexes generate double-strand breaks
(DSB) by cleaving the target DNA, resulting in indel
mutations and subsequently, loss of gene function.
Furthermore, the use of multiple sgRNAs can efficiently
induce large deletions in the target gene. In this study, to
avoid any conflicts with patents or material transfer
agreements, Tff1-KO mice were generated without any
external genes (e.g. neomycin resistance) using the
multiple sgRNAs and Cas9. This model will allow us to
more accurately study the effects of genetic alteration
during gastric tumorigenesis.
Materials and Methods
Animals
All mice were purchased from Taconic Biosciences
(Dae Han Biolink, Co., Ltd., Republic of Korea) and
were maintained in the specific pathogen-free (SPF)
facility of the Yonsei Animal Research Center. Animal
suffering was minimized and all experiments were
performed in accordance with the Korean Food and
Drug Administration (KFDA) guidelines for animal
research. The experimental protocols for generating the
genetically engineered mouse models were approved by
the Institutional Animal Care and Use Committee
(IACUC) at Yonsei University.
Preparation of CRISPR/Cas9 mRNA and sgRNAs
Cas9 mRNA and sgRNAs were synthesized in vitro
using the mMESSAGE mMACHINE® T7 Ultra and
MEGAshortscript T7 kits (Ambion), respectively. Cas9
mRNA and sgRNAs were diluted in RNase-free
injection buffer (0.25 mM EDTA, 10 mM Tris at pH 7.4)
to obtain the working concentration before microinjection
[12,13]. PCR-amplified DNA templates containing the
following target sequences were used for sgRNA synthesis:
sgRNA#1, CTACAGGTTCATTCCAGCAG; sgRNA#2,
GGTTCATTCCAGCAGAGGAG; sgRNA#3, GCAGT
GTAAGCCCAGCTGGA; sgRNA#4, ACTCTAAGCA
AATAGACCGG; sgRNA#5, CTAGGACCTATGAGG
ATGCA; sgRNA#6, GTATCAGTGGCTTGTGGCAG;
sgRNA#7, TGTGTAAGCTGAGCTTTGCC; sgRNA#8,
GATGTCCCTTGAGTGGGAGG.
Microinjection
Microinjections were performed as described previously
[14]. Briefly, 4-6-week-old B6 mice were superovulated
by intraperitoneal injection of pregnant mare serum
gonadotropin (PMSG, Sigma) and human chorionic
gonadotropin (hCG, Sigma) and fertilized embryos were
collected. A mixture of Cas9 mRNA (10 ng/µL) and
four sgRNAs (50 ng/µL each) were microinjected into
the cytoplasm of mouse zygotes using a Piezo-driven
manipulator (Prime Tech). Injected embryos were then
transferred into the oviducts of foster mother mice.
Screening and genotyping
To screen the founder mice carrying Tff1 mutations,
PCR was performed using the following primers: 5'-
GGTCATATAGGCATGTGTAAGGA-3' (Tff1 F) and 5'-
CCTAGGCAGTTATAAGGTCCCT-3' (Tff1 R). Mice
generated from intercrosses between heterozygous mice
were genotyped by PCR using Tff1 F (used for
screening) and Tff1 R1 (5'-TCCTACCGGCAAAGGT
CCTA-3') primers. PCR was performed as follows: pre-
denaturation of 3 min at 95oC; 10 cycles of 30 s at 95oC,
60 s at 65oC (reduced by 0.5oC per cycle), and 30 s at
68oC; 30 cycles of 30 s at 95oC, 30 s at 60oC, and 60 s
at 72oC; and 5 min at 72oC. PCR products were
electrophoresed on 2-3% of agarose gels and visualized
with a ChemiDoc system (Bio-Rad).
Necropsy and stomach fixation
8- or 14-month-old mice were euthanized in CO
2
chambers that complied with the code of ethics for
animal experimentation. Immediately after each sacrifice,
the stomach was expanded by injection of 4% phosphate-
buffered formalin (4% PFA, Biosesang Co., Ltd.,
Republic of Korea) and cut along the line of the greater
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curvature. The cut stomach tissue was spread flat on 3M
paper without touching the glandular region. The flattened
tissue was embedded in paraffin and then fixed in 4%
PFA overnight. Organ and body weights were measured
and relative organ weight was calculated using the
following formula: (organ weight/total body weight) ×100.
Histopathological analysis
For histopathological analyses, paraffin-embedded
blocks were cut into 5 µm sections using a microtome
(RM2235, Leica). Sections were deparaffinized with
xylene (UN1307, Baker) three times, each for 20 min.
Sections were dried at room temperature after two
washes in 100% EtOH for 5 min each wash. For
hematoxylin and eosin (H&E) staining, sections were
stained with 0.1% Mayer’s hematoxylin for 10 min and
0.5% eosin in 95% EtOH for 10 min. After H&E
staining, sections were washed in distilled H
2
O until the
eosin stopped streaking. They were then dipped in 50%
EtOH 10 times, 70% EtOH 10 times, 95% EtOH for
30 s, and 100% EtOH for 1 min. Samples were then
covered with mounting solution (Thermo Scientific) and
diagnosed by a pathologist under a light microscope
(BX43, Olympus).
Results
Generation of Tff1-KO mice by multiple sgRNAs/Cas9
microinjection
To generate Tff1-KO mice we deleted exon 1 using
multiple sgRNAs targeting the promoter and intron 1 of
Tff1. To minimize off-target effects and maximize on-
target activity of CRISPR/Cas9, we designed eight
different sgRNAs using CRISPR Design (http://crispr.
mit.edu, Figure 1A). Two combinations consisting of
four sgRNAs targeting either the promoter or intron 1
were used (Table 1, Figures 1A and B). The targeting
efficiency of combination 1 (sgRNA 1, 2, 5, 6; 36%) in
the embryos was higher than that of combination 2
(sgRNA 3, 4, 7, 8; 6%; Table 1, Figure 1B), resulting in
seven candidates with large deletions (five in combination
1 and two in combination 2), as identified by PCR
screening (Figure 1B). Each candidate was validated by
sequencing analysis, which confirmed various large
deletion mutations (800-1100 nucleotides), eliminating
exon 1 of Tff1 (Figure 1C). Finally, we selected candidate
#14, which carries an 856-bp deletion mutation, as the
Tff1-KO mouse strain to use for further experiments
(Figure 1C and D). Genotypes of KO mice were confirmed
by PCR (Figure 1D). Homozygous KO mice generated
from intercrosses between heterozygous mice were born
at the expected Mendelian ratio (Table 2), indicating that
Tff1 deficiency does not result in embryonic lethality.
Body weight reduction in Tff1-KO male mice
To examine the phenotypic properties of Tff1-KO
mice, we measured body weight weekly throughout the
experimental period. Interestingly, the body weight of
male Tff1-KO mice significantly decreased in comparison
to wild-type (WT) mice after 4 weeks, whereas the body
weight of female mice was not affected by Tff1
deficiency (Figures 2A and B). To further investigate the
reason for the change in body weight, we measured the
weight of each organ of male mice at the end stage of
experiments when they were approximately 40 weeks
old. Upon sacrifice, the weight of specific organs,
including the heart, liver, kidney, lung, and spleen, were
immediately measured using an electronic balance. At
the end stage, the overall body weight loss was still
observed in male Tff1-KO mice, with weight loss seen
in the liver, heart, and spleen (Figure 2C). However,
there was no significant difference between WT and
Tff1-KO mice when organ weight was normalized to
total body weight (data not shown). This result shows
that Tff1 deficiency induces total body weight loss and
organ weight loss in male mice.
Loss of Tff1 promotes stomach lesions, especially in
the antrum
As presented in Figure 3A, macroscopic observations
clearly showed an increase in the thickness of the antrum
and mucosal projections in Tff1-KO mice (lower panel).
Table 1. CRISPR/Cas9-mediated gene targeting
sgRNA 
combination
Cas9 mRNA 
(ng/µL)
Name of 
sgRNAs
sgRNA 
(ng/µL each)
No. of embryos 
injected
No. of embryos 
transferred
(%)
No. of 
newborns
(%)
No. of mutants
(%)
Combination 1 10 1, 2, 5, 6 50 131 113 (86) 15 (13) 5 (33)
Combination 2 10 3, 4, 7, 8 50 146 108 (74) 43 (40) 2 (4)
260 Hyejeong Kim et al.
Lab Anim Res | December, 2018 | Vol. 34, No. 4
Gastric lesions were not seen in WT mice (upper panel).
However, morphological changes in the fundus were not
observed in either mouse strain. To diagnose distinct
morphological features, we performed histopathological
analysis on 8- and 14-month-old Tff1-KO mice. In 8-
month-old mice, Tff1 deficiency resulted in a conspicuous
histological feature of antral dysplasia, characterized by
irregular morphology of the gastric gland, occurrence of
atypical cells, and an increase in infiltration of inflammatory
cells when compared to WT mice with normal gland
architecture (Figure 3Ba-d, Table 3). Adenoma was
observed in 14-month-old Tff1-KO mice. Atypical
epithelial gland architecture was observed in the cancerous
region, with growth of the stromal stalk and marked
inflammation (Figures 3Be and f). Some gland structures
were observed in the adjacent region, but they were hard
to distinguish from normal glandular architecture
(Figures 3Be and f). Cystic dilatation was seen at the
base mucosa in 14-month-old Tff1-KO mice (Figure
Figure 1. (A) CRISPR/Cas9 targeting strategy to generate Tff1-KO mice. Blue arrows #1-
8 indicate the location and orientation of sgRNAs designed to target specific sites. Exons
and introns are indicated with boxes and lines, respectively. PCR primers (F, forward; R,
reverse) for genotyping are denoted by red arrows. (B) PCR screening results for
newborns edited by Cas9 with sgRNAs 1, 2, 5, and 6 (combination 1) or 3, 4, 7, and 8
(combination 2). Mice carrying deletion mutations are highlighted in red. (C) Sequencing
results for candidate newborns from combination 1 (upper panel) and 2 (bottom panel).
The protospacer adjacent motif (PAM) and target sequences of sgRNAs are shown in red
and blue, respectively. The symbol, “-”, indicates a single-nucleotide deletion. (D) PCR
genotyping results for heterozygous (HT), homozygous (KO), and wild-type (WT) mice.
Each arrow indicates WT- (1181 bp) and KO-specific (325 bp) bands.
Table 2. Genotyping distribution
No. of mice +/+ +/- -/- female male
35 8 16 11 19 16
Ratio 1 2 1.3 1 0.8
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3Bg and h, Table 3). Indeed, all Tff1-KO mice showed
precancerous or cancerous changes in the antrum, but no
severe alterations were found in the fundus when compared
with WT mice (data was not shown). Taken together,
Tff1 deficiency promotes gastric tumorigenesis, especially
in the antrum region, as previously reported [8].
Discussion
We report the generation of Tff1-KO mice using
CRISPR/Cas9 and the analysis of the gastric phenotype
of homozygous null mice to determine their utility as a
stomach cancer model. We eliminated exon 1 of Tff1,
including the initiation codon, using Cas9 with multiple
sgRNAs. Consistent with previous results, [8] Tff1
deficiency in mice led to morphological changes in the
antrum and the presence of atypical cells in the gastric
glands. Although the antral and pyloric mucosa were
thicker in Tff1-KO mice, the fundus did not show any
obvious abnormality. Both sexes were equally affected
and these phenotypes were seen in 54% of Tff1-KO mice
examined. At 14 months, 26% of KO mice exhibited
adenoma and many cancerous changes in the antrum
region. These results are consistent with the lack of
TFF1 expression observed in human gastric carcinomas
[15-18]. Gastric cancer patients usually suffer from
symptoms such as vomiting, stomach pain, and weight
loss. Weight loss occurs in less than 40% of patients with
early-stage gastric cancer and in approximately 60% of
patients with advanced gastric cancer [19,20]. Unlike
previous embryonic-stem (ES)-cell-based Tff1-KO mice,
which showed no weight loss compared to WT mice
[21], significant weight loss was observed in male Tff1-
KO mice in our study. Consistent with our results,
weight loss and muscle wasting (cachexia) are more
frequently observed in male than female cancer patients
[22]. Although further studies regarding body weight are
needed, these results suggest that the gender difference
seen in gastric cancer patients may be influenced by Tff1
expression. In addition, the difference between our Tff1-
KO mice and ES-cell-based Tff1-KO mice may be due
to the differences in gene targeting processes used. The
expression of NeoR, which is inserted in ES-cell-based
KO mice to enable screening of correctly targeted clones
Figure 2. (A-B) Body weight changes in WT (black, n=7) and Tff1-KO (red, n=7) mice. Total body weights of male (A) and female
(B) mice were measured once a week from 4 weeks to 36 weeks. Data are presented as mean±SEM (Student’s t-test, *P<0.05,
**P<0.01, ***P<0.001). (C) Mean weights (g) of total body, liver, kidney, lung, heart, and spleen in male WT and Tff1-KO mice after
sacrifice. Data are presented as mean±SEM (WT, n=2; KO, n=7).
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[8], can affect gene expression and cell physiology
[23,24]. For example, the NeoR cassette can lead to an
increase in the expression of the endogenous c-myc
gene, which is commonly amplified or overexpressed in
primary tumors [25]. On the other hand, our Tff1-KO
mice were produced using the CRISPR/Cas9 system,
without inserting exogenous antibiotic resistance genes.
Therefore, these Tff1-KO mice will provide us a benefit
to gain further insights into the more accurate genetic
and environmental influences in gastric cancer.
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